I’m a disabled American. Trump’s policies will be a disaster for people like me.
By Ari Ne'eman,
Vox
| 11. 09. 2016
It’s the early hours of Wednesday morning, and I’m watching my friends fear for their lives on Twitter. We’ve just learned that Donald J. Trump will be the next president of the United States. People are talking about the likelihood that they’ll lose health insurance when the Affordable Care Act is repealed, the fear that the attendant who helps them get dressed in the morning will no longer be available when Medicaid is slashed, the possibility that their conversations with their therapist may no longer be private, the impossibility of paying out of pocket for the medications, in-home care, assistive technology, and other essential parts of disabled life. Like many other people with disabilities, we’re terrified by the prospect of a Trump administration and what it may bring to people like us.
Much has been made over (now President-elect) Donald Trump’s mocking of disabled New York Times reporter Serge Kovaleski last year. Spurred by the widespread outrage at Trump’s cruelty, the Democratic National Committee made disability rights a high-profile theme of its 2016 convention. But for most disability...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...